Last updated on November 2017

ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an investigational bioabsorbable vascular scaffold manufactured by Abbott. Absorb™ is referred to as a scaffold to indicate that it is a temporary structure.


Brief description of study

ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an investigational bioabsorbable vascular scaffold manufactured by Abbott. Absorb™ is referred to as a scaffold to indicate that it is a temporary structure.

Detailed Study Description

Abbott's Absorb™ BVS is made of polylactide, a naturally dissolvable material that is commonly used in medical implants such as dissolving sutures. ABSORB III™ is the first U.S. clinical trial to evaluate the potential benefits and safety of Absorb™ in comparison to a medicated metallic cardiac stent, also called a drug eluting stent, in patients with CAD. Absorb BVS™ is approved for use outside of the US. More than 25,000 patients worldwide have received an Absorb BVS™. The clinical trial will enroll approximately 2,250 patients, the majority expected in the United States.

Clinical Study Identifier: TX81285

Contact Investigators or Research Sites near you

Start Over

Kimberly Crowe, MSN

Holy Cross Jim Moran Heart and Vascular Research Institute
Fort Lauderdale, FL USA